VisiJet Appoints Richard L. Lindstrom, M.D. as Medical Director; Recognized Surgeon, Scientist and Academic to Oversee Scientific Direction of Company.
IRVINE, Calif.--(BUSINESS WIRE)--June 30, 2003
VisiJet, Inc. (OTCBB:VJET), a medical device company developing innovative products that advance ophthalmics, has announced the appointment of Richard L. Lindstrom M.D., as medical director to guide the company's product development, clinical studies and scientific growth.
Lindstrom, a well-known ophthalmologist and leader in corneal, cataract, refractive and laser surgery, brings nearly 30 years' expertise in active practice as well as research, editorial and board experience to his new position.
"I am gratified to be involved with a company as forward thinking as VisiJet," stated Dr. Lindstrom. "I have watched the waterjet technology evolve and I am as excited about its potential as I was when first working with lasers and other innovations in our industry. I anticipate that the company's first product, the HydroKeratome, will fast play a significant role in refractive surgery."
He added, "I also believe the waterjet technology will have success for other applications in ophthalmology as well as in medicine in general."
Dr. Lindstrom has received numerous scientific, teaching and research awards. A graduate of the University of Minnesota where he received both his undergraduate degrees in Liberal Arts and Science and his Doctor of Medicine degree, Lindstrom's academic experience began with his role as Assistant Professor of Ophthalmology at Texas Southwestern Medical School. He was a full Professor of Ophthalmology at the University of Minnesota Medical School where he was granted the Harold G. Scheie Research Chair in Ophthalmology. Some of his many awards include the Lifetime Achievement Award from the International Society of Refractive Surgery 2002, the American Academy of Ophthalmology Refractive Surgery Interest Group Honor Lecture Award, and the Binkhorst Medal lecture from the American Society of Cataract and Refractive Surgery. He has presented over 27 named lectures including the Choyce Medal Lecture at the United Kingdom Intraocular Implant Society, the Irving H. Leopold Lecture at Wills Eye Hospital in Philadelphia and the Lans Distinguished Refractive Surgery Lecture at the 1990 World Congress in Singapore.
Dr. Lindstrom holds 28 patents in ophthalmology including intraocular lens implant technology, corneal preservation, irrigation solutions, visoelastic solutions, intraocular lenses, and associated instruments. He has designed many intraocular lenses and instruments. In addition, Dr. Lindstrom is active on multiple editorial boards including serving as an Associate Editor of the Journal of Cataract and Refractive Surgery, the CLAO Journal, the Journal of Corneal & Refractive Surgery and Ophthalmic Surgery. He is the Chief Medical Editor for Ocular Surgery News, and Ocular Surgery News International.
"We, like the rest of the industry, are awed at Dr. Lindstrom's experience, knowledge and dedication to ophthalmology," said Randy Bailey, President and CEO of VisiJet. "His guidance, expertise and scientific acumen help assure our company of a solid foundation with incredible potential. Everyone in the company, from R&D to sales, is pleased that Dr. Lindstrom has become part of our vision."
About VisiJet, Inc.
VisiJet, Inc. is a medical device company based in Irvine, California, focused on the development and marketing of innovative ophthalmic applications that will result in faster, safer and more efficacious procedures in two of the largest surgical markets in the world: refractive and cataract surgeries. VisiJet's lead products, the HydroKeratome(R) and Pulsatome(R), utilize the Company's proprietary and patented waterjet technology that uses a high-pressure micro beam of water the diameter of a human hair to cut ocular tissue. The FDA-approved HydroKeratome(R), uses the waterjet technology to cut the cornea as required in LASIK surgery. The Pulsatome(R), currently under development, is a device that uses waterjet technology to remove cataracts -- the most performed surgical procedure in the world. VisiJet, Inc. is located at 188 Technology Drive, Suite D, Irvine, CA. PH: 949-450-1660, FX: 949-453-9652, Investor Relations: 949-450-1660 ext. 28. Website: www.visijet.com
Except for historical information contained herein, the matters discussed in this news release are forward-looking statements within the meaning of the Securities Exchange Act that involve risks and uncertainties that could cause actual results to differ materially from those expressed. These matters include, but are not limited to, information about the Company's technologies and products, financial situations, or business opportunities. This news release shall not constitute an offer to sell or the solicitation of an offer to sell any of these securities.
|Printer friendly Cite/link Email Feedback|
|Date:||Jun 30, 2003|
|Previous Article:||Teledyne Awarded Over $50 Million DOE Space Power Contract.|
|Next Article:||InKine Initiates Phase IV Constipation Study Using Visicol Tablets.|